CN102351878B - Isoxazole derivatives as well as preparation method and application thereof - Google Patents
Isoxazole derivatives as well as preparation method and application thereof Download PDFInfo
- Publication number
- CN102351878B CN102351878B CN201110243775.8A CN201110243775A CN102351878B CN 102351878 B CN102351878 B CN 102351878B CN 201110243775 A CN201110243775 A CN 201110243775A CN 102351878 B CN102351878 B CN 102351878B
- Authority
- CN
- China
- Prior art keywords
- compound
- acceptable salt
- pharmacy acceptable
- preparation
- platelet aggregation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention belongs to the technical field of platelet aggregation inhibiting drugs, and provides isoxazole derivatives with a structure shown in the formula I and pharmaceutically acceptable salts thereof. In the formula I, R<1> is acetoxyl; R<2> is H, methyl or ethyl; and R<3> and R<4> are H, methyl, isopropyl, cyanomethyl, ethoxycarbonyl or chlorophenyl. The invention also relates to a preparation method of the compounds, and simultaneously discloses pharmaceutical compositions with the compounds or pharmaceutically acceptable salts of the compounds as the active effective ingredient, and application of the pharmaceutical compositions used as platelet aggregation inhibiting drugs.
Description
Technical field
The invention belongs to medical technical field, or rather, the pharmaceutical composition that relates to a class and there is Isoxazole derivative of antiplatelet aggregative activity and preparation method thereof, contain them and as the purposes of medicament for resisting platelet aggregation.
Background technology
Take in recent years coronary artery thrombus and cerebral thrombosis as the sickness rate of main thrombotic disease in rising trend, serious harm human health.Platelet aggregation is a key link in normal clotting mechanism, and hematoblastic adhesion, gathering, release reaction cause thrombosis.Therefore anticoagulant medicine plays a significant role in treatment thrombus disease, is the focus that people study always.
Clinically, acetylsalicylic acid is as medicament for resisting platelet aggregation widespread use.Although acetylsalicylic acid can be tolerated by most people, yet even low dose also may cause part population gastrointestinal discomfort sometimes,, also there is Aspirin Resistance in even serious gastrointestinal hemorrhage or hematencephalon in recent years.
Adp receptor antagonist Ticlopidine, clopidogrel also come with some shortcomings clinically.
Need at present more safe and effective such medicine of searching badly.
Summary of the invention
One object of the present invention is, discloses a kind of Isoxazole derivative and pharmaceutical salts thereof of novel texture.
Another object of the present invention is, discloses the preparation method of Isoxazole derivative and pharmaceutical salts thereof.
A further object of the present invention is, discloses to take the pharmaceutical composition that a class Isoxazole derivative and pharmaceutical salts thereof be main active ingredient.
A further object of the invention is, one class Isoxazole derivative and pharmaceutical salts thereof disclosed, application as antiplatelet drug aspect, particularly at the coronary syndrome causing because of platelet aggregation for the preparation of prevention or treatment, myocardial infarction, myocardial ischemia, the purposes of cardiovascular and cerebrovascular diseases medicament aspect.
Now, in conjunction with the object of the invention, content of the present invention is described in detail.
The present invention is specifically related to compound and the pharmacy acceptable salt thereof of general formula I structure:
Wherein:
R
1for: hydrogen, C
1-C
4straight or branched carbalkoxy.
R
2for: hydrogen, C
1-C
4straight or branched alkyl.
R
3, R
4for: hydrogen, C
1-C
4straight or branched alkyl, C
1-C
4straight or branched alkyl cyano group, phenyl, halogeno-benzene, C
1-C
4straight or branched carbalkoxy.
Preferred following compound and pharmacy acceptable salt thereof:
Wherein:
R
1for: hydrogen, methanoyl, acetoxyl group.
R
2for: hydrogen, methyl, ethyl.
R
3, R
4for: hydrogen, methyl, sec.-propyl, first cyano group, ethoxycarbonyl, chlorinated benzene.
More preferably its pharmacy acceptable salt of following compound:
I-1 5-(2-((3-isopropyl oxazole-5-yl) amino)-2-oxoethyl)-4,5,6,7-tetramethylene sulfide is [3,2-c] pyridine-2-yl acetate also;
I-2 5-(2-(4-(first cyano group) isoxzzole-5-base is amino)-2-oxoethyl)-4,5,6,7-tetramethylene sulfide is [3,2-c] pyridine-2-yl acetate also;
I-3 5-((2-(3,5-dimethyl isoxazole-4-yl) amino)-2-oxoethyl)-2-acetoxyl group-4,5,6,7-tetramethylene sulfide is [3,2-c] pyridine also;
I-4 5-(2-(2-acetoxyl group-6,7-dihydro-thiophene is [3,2-c] pyridine-5 (4H)-yl also) kharophen)-4-ethoxycarbonyl isoxzzole;
I-5 5-(2-(2-acetoxyl group-6,7-dihydro-thiophene is [3,2-c] pyridine-5 (4H)-yl also) kharophen)-3-methyl-4-ethoxycarbonyl isoxzzole;
I-6 5-(2-(5-methyl isoxzzole-3-base is amino)-2-oxoethyl)-4,5,6,7-tetramethylene sulfide is [3,2-c] pyridine-2-yl acetate also;
I-7 5-(1-(3-(2-chloro-phenyl-) isoxzzole-5-base is amino)-1-oxo butyl-2-yl)-4,5,6,7-tetramethylene sulfide is [3,2-c] pyridine-2-base propionic ester also.
Formula I compound pharmacy acceptable salt refers to: compound and mineral acid, organic acid salify.Wherein preferred: hydrochloride, hydrobromate, hydriodate, vitriol, hydrosulfate, phosphoric acid salt, acetate, propionic salt, butyrates, lactic acid salt, mesylate, tosilate, maleate, benzoate, succinate, tartrate, Citrate trianion, fumarate, taurate etc.
The syntheti c route of formula I compound is as follows:
Wherein X is Cl, Br; R
1～R
4as aforementioned definitions.
Intermediate III and 5,6,7,7a-tetramethylene sulfide also [3,2-c] pyridine-2 (4H)-one hydrochloride, under the existence such as morpholine, be take acetonitrile as solvent, and 30～60 ℃ of reactions, make intermediate compound IV.Intermediate compound IV, 0～40 ℃ by acid anhydrides acidylate, makes Compound I.
Reaction make various compounds or products therefrom is dissolved in DMF, acetone, methyl alcohol, ethanol, Virahol, ether or DMSO drip mineral acid, organic acid is made pharmacy acceptable salt.
Specifically products therefrom is dissolved in DMF, acetone, methyl alcohol, ethanol or DMSO, drip acidic alcohol to pH be 2, make hydrochloride.Or products therefrom is dissolved in to DMF, acetone, methyl alcohol or ethanol, and the molar lactic acid such as add, obtain its lactic acid salt.
The disease that this compounds causes because of platelet aggregation for the treatment mankind is effective.Although compound of the present invention can be without the direct administration of any preparation, described various compounds are preferably used with the form of pharmaceutical preparation, and route of administration can be parenteral route (as vein, muscle administration) and oral administration.
The pharmaceutical composition of the compounds of this invention is prepared as follows: use standard and conventional technology; the compounds of this invention acceptable solid or liquid vehicle on technology of pharmaceutics are combined, and make it at random on technology of pharmaceutics acceptable auxiliary and vehicle and be combined and be prepared into particulate or microballoon.Solid dosage comprises tablet, discrete particles, capsule, slow releasing tablet, sustained release pellet etc.Solid carrier can be at least one material, and it can serve as thinner, flavouring agent, solubilizing agent, lubricant, suspension agent, tackiness agent, disintegrating agent and coating agent.Inert solid carrier comprises trimagnesium phosphate, Magnesium Stearate, smoothers sugar, lactose, pectin, propylene glycol, Polysorbate 80, dextrin, starch, gelatin, cellulose substances such as methylcellulose gum, Microcrystalline Cellulose, low melt point paraffin, polyoxyethylene glycol, N.F,USP MANNITOL, theobroma oil etc.Liquid dosage form comprises solvent, suspension for example injection, pulvis etc.
The amount of the active ingredient containing in pharmaceutical composition and unit dosage form (the compounds of this invention) can specifically be applied according to the situation of patient's the state of an illness, diagnosis, and the amount of compound used or concentration regulate in a wider scope.Conventionally, 0.5～90% (weight) that the scope of active compound amount is composition, another preferred scope is 0.5～70%.
Compound or its pharmacy acceptable salt with formula I structure of the present invention has obvious restraining effect aspect platelet aggregation.
Below by pharmacodynamic experiment, further illustrate the antithrombotic acitivity of the compounds of this invention.
To rat platelet aggregation restraining effect
Medicine and preparation: compound is made into suspension for animals administer with 0.5%CMC; Adenosine diphosphate (ADP) (ADP) (SERVA company, lot number 01993).
Animal: male rat, Tianjin Inst. of Materia Medica laboratory animal room provides, animal conformity certification number: No. 001st, Tianjin animal word.
Instrument: PK121R type whizzer (Italian ALC International SPL product), SPA-3 type PPP platelet aggregation instrument (Shanghai Kodak testing tool factory).
Test method: male Wistar rat, body weight 300g left and right, per os gavage gives Clopidogrel Hydrogensulfate and analogue thereof, and dosage is 10mg/kg, administration volume is 10mL/kg, after 2h, etherization, aorta abdominalis blood sampling, 3.8% Sodium Citrate anti-freezing, whole blood is 9: 1 with the ratio of antithrombotics, and the centrifugal 7min of 1000rpm, prepares platelet rich plasma (PPP).With PPP, adjust PRP, make its platelet count remain on 2 * 106/ml.Get PRP and add in test cup, 37 ℃ of temperature are incubated 10min.With PRP, return to zero, PPP adjusts 100%, and the ADP (final concentration is 5 μ M) of take is inductor, by turbidimetry, with SPA-3 type PPP platelet aggregation instrument, measures platelet aggregation percentage ratio, with t-check, carry out statistics comparison, compound sample the results are shown in Table 1 to rat platelet aggregation restraining effect.
Table 1 compound sample is to rat platelet aggregation restraining effect result
From above pharmacological evaluation, compound of the present invention can obviously suppress the platelet aggregation of ADP induction.Therefore, they can be used for the coronary syndrome that prevention or treatment cause because of platelet aggregation, myocardial infarction, the cardiovascular and cerebrovascular diseases such as myocardial ischemia.
Embodiment
Below in conjunction with embodiment, the present invention is described further, and embodiment is only indicative, never means that it limits the scope of the invention by any way.Described compound is through high performance liquid chromatography (HPLC), and thin-layer chromatography (TLC) detects.Can adopt subsequently such as infrared spectra (IR), nuclear magnetic resonance spectrum (
1hNMR,
13c NMR), mass spectrum (MS) etc. is further confirmed its structure.
Reference example 1: the preparation of intermediate III-1
In the reaction flask that stirring, condenser, thermometer are housed, add 12.6g 3-sec.-propyl-5-amido isoxazole, after being dissolved with 50ml DMF, add 20.2g triethylamine, at-10 ℃～5 ℃, stir, drip the mixed solution of chloroacetyl chloride (16.9g) and methylene dichloride (30m1), after low-temp reaction 3h (flaggy demonstration reacts completely) stirring at room 1h, reaction solution is poured in 100ml cold water, fully stirred, filter, obtain brown solid (HPLC:90.5%).Rf=0.66[single-point, developping agent: v (sherwood oil): v (ethyl acetate)=1: 2]
Method with reference to reference example 1 can conveniently be prepared compound: intermediate III-2～III-6, by 2-bromo butyryl bromide, replaces chloroacetyl chloride to obtain III-7 (compound list is in Table 2).
Table 2 intermediate III-2～III-7 list
Embodiment 1: the preparation of intermediate compound IV-1
In the reaction flask that stirring, condenser, thermometer are housed, add successively 20.2g intermediate III-1,100mL acetonitrile and 20.2g morpholine, under nitrogen protection, add 19.1g 5,6,7,7a-tetramethylene sulfide [3,2-c] pyridine-2 (4H)-one hydrochloride.After 40-50 ℃ of reaction 3h, stop heating, be cooled to room temperature.To adding distil water 100ml in reaction solution, ethyl acetate extraction (100ml * 3), merges organic phase, anhydrous sodium sulfate drying, filters, and filtrate decompression is steamed and desolventized, resistates is separated with silica gel column chromatography, obtains white solid IV-1 (HPLC:95.5%).HRMS(m/z)[M+H]
+：322.1220。
Method with reference to embodiment 1 can conveniently be prepared compound: intermediate compound IV-2～IV-7 (particular compound is in Table 3).
Table 3 intermediate compound IV-2～IV-7 list
Embodiment 2:5-(2-(5-methyl isoxzzole-3-base is amino)-2-oxoethyl)-4,5,6,7-tetramethylene sulfide is the preparation of [3,2-c] pyridine-2-yl acetate (Compound I-6) also
In the reaction flask that stirring, condenser, thermometer are housed, add successively 35.2g intermediate compound IV-1,100mL acetonitrile and a small amount of triethylamine; under nitrogen protection, drip diacetyl oxide, 30 ℃ are stirred 3h, solvent evaporated; anhydrous methanol recrystallization, obtains light yellow solid I-6 (HPLC:99.2%).
1H?NMR(CDCl
3，400MHz)：2.266(s，3H，CH
3COO-)，2.387-2.388(d，3H，-CH
3)，2.816-2.842(t，2H，-CH
2CH
2-)，2.908-2.936(t，2H，-CH
2CH
2-)，3.309(s，2H，-CH2CO-)，3.592(s，2H，-CH
2-)，6.290(s，1H，-CH＝)，6.709-6.711(d，1H，-CH＝C(O-)-CH
3)，9.640(s，1H，-NH-)；HRMS(m/z)[M+H]
+：336.1013。
Method with reference to embodiment 2 can conveniently be prepared Compound I-1～I-5, with propionic anhydride, replaces diacetyl oxide to make Compound I-7 (particular compound is in Table 4).
Table 4 Compound I-1～I-5 list
Embodiment 3:
Compound I-1 one-tenth hydrochloride: get I-1 white solid product 4.5g, be dissolved in 20mL dehydrated alcohol.Ice-water bath is cooled to 5 ℃, drip 11.0% ethanol solution hydrochloride to pH be 2, continue at stir about 1h under ice-water bath.Filter, obtain white solid.
For the pharmaceutical composition of Isoxazole derivative of the present invention is described more fully, following FORMULATION EXAMPLE is provided below, described embodiment is only for explanation, rather than for limiting the scope of the invention.Described preparation can be used any active compound and the salt thereof in the compounds of this invention, preferably uses the compound described in embodiment 1-3.
Embodiment 4:
By following compositions, prepare hard gelatin capsule:
Preparation technology: supplementary material is dry in advance, cross 100 mesh sieves standby.Press recipe quantity by after mentioned component mixing, be packed in hard gelatin capsule.
Embodiment 5:
By following compositions, prepare tablet:
Preparation technology: supplementary material is dry in advance, cross 100 mesh sieves standby.First the auxiliary material of recipe quantity is fully mixed.Bulk drug is added in auxiliary material to increase progressively dilution method, and each added-time fully mixes 2-3 time, guarantees that medicine and auxiliary material fully mix, cross 20 mesh sieves, dry 2h in 55 ℃ of ventilated drying ovens, dry particle is crossed 16 mesh sieves and is arranged, measure intermediate content, mix compressing tablet on tabletting machine.
Embodiment 6:
The preparation of injection liquid:
Preparation method: get activeconstituents and join in the water for injection that dissolves sorb ester and propylene glycol, add medicinal basic to regulate pH value to make its dissolving to 4-8.Add gac, whip attachment 30min, carbon removal, smart filter, embedding, sterilizing.
Embodiment 7:
The preparation of injection lyophilized powder:
The hydrochloride 100mg of Compound I-1
Medicinal basic 0.1-7.0%
N.F,USP MANNITOL 55-85%
Preparation method: get activeconstituents and add water for injection, regulate pH value to make its dissolving to 4-8 with medicinal basic.Add N.F,USP MANNITOL again, by the requirement of injection, carry out autoclaving, add gac, adopt filtering with microporous membrane, filtrate is carried out packing, adopts freeze-drying, makes loose block, and sealing, obtains.
Claims (8)
1. compound or its pharmacy acceptable salt with formula I structure:
Wherein:
R
1for: acetoxyl group;
R
2for: hydrogen, methyl, ethyl;
R
3, R
4for: hydrogen, methyl, sec.-propyl, cyanogen methyl, ethoxycarbonyl, chlorophenyl.
2. compound or its pharmacy acceptable salt with following structure:
3. compound as claimed in claim 1 or 2 or its pharmacy acceptable salt, its pharmacy acceptable salt is: compound and mineral acid, organic acid salify.
4. compound as claimed in claim 3 or its pharmacy acceptable salt, its pharmacy acceptable salt is: hydrochloride, hydrobromate, hydriodate, vitriol, hydrosulfate, phosphoric acid salt, acetate, propionic salt, butyrates, lactic acid salt, mesylate, tosilate, maleate, benzoate, succinate, tartrate, Citrate trianion, fumarate, taurate.
5. the preparation method of claim 1 Chinese style I compound; it is characterized in that: intermediate III and 5,6,7; 7a-tetramethylene sulfide [3; 2-c] pyridine-2(4H)-one hydrochloride, under morpholine exists, take acetonitrile as solvent; 30-60 ℃ is reacted to obtain intermediate IV; after acid anhydrides acidylate, make chemical compounds I again, wherein X is Cl or Br, R
1～R
4as claim 1 definition,
6. a pharmaceutical composition for platelet aggregation-against, it comprises compound as claimed in claim 1 or 2 or its pharmacy acceptable salt and one or more pharmaceutical carriers for the treatment of significant quantity.
7. the compound described in claim 1 or 2 or its pharmacy acceptable salt are in the application aspect medicament for resisting platelet aggregation.
8. application as claimed in claim 7, the purposes aspect the cardiovascular and cerebrovascular diseases medicament causing because of platelet aggregation for the preparation for the treatment of.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201110243775.8A CN102351878B (en) | 2011-08-24 | 2011-08-24 | Isoxazole derivatives as well as preparation method and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201110243775.8A CN102351878B (en) | 2011-08-24 | 2011-08-24 | Isoxazole derivatives as well as preparation method and application thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102351878A CN102351878A (en) | 2012-02-15 |
| CN102351878B true CN102351878B (en) | 2014-04-09 |
Family
ID=45575546
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201110243775.8A Active CN102351878B (en) | 2011-08-24 | 2011-08-24 | Isoxazole derivatives as well as preparation method and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102351878B (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103896962B (en) * | 2014-03-20 | 2016-09-14 | 天津药物研究院 | One class thienopyridine esters derivative containing substituted piperazinyl and its production and use |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0125708D0 (en) * | 2001-10-26 | 2001-12-19 | Generics Uk Ltd | Novel compounds and processes |
| CN102093385B (en) * | 2010-12-30 | 2013-03-27 | 天津药物研究院 | Schiff base compounds as well as preparation method and application of Schiff base compounds |
-
2011
- 2011-08-24 CN CN201110243775.8A patent/CN102351878B/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CN102351878A (en) | 2012-02-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101402641B (en) | Oxime derivatives containing thienopyridine, preparation method and application thereof | |
| TW200825094A (en) | Therapeutic pyrazolyl thienopyridines | |
| TW200530227A (en) | Benzimidazole derivative and use thereof | |
| JP5575979B2 (en) | Thienopyridine ester derivatives containing cyano groups, their preparation, use and compositions | |
| CN101284838B (en) | Ethylene imine derivates with thienopyridine, preparation method and applications thereof | |
| CN104447867A (en) | Thienopiperidine derivative, preparation method and application thereof | |
| CN102351877B (en) | Thiophene derivative, its preparation method and its application | |
| CN103058972B (en) | Phenyl C-glucoside derivatives containing cyclohexane structure as well as preparation method and application thereof | |
| CN101974015B (en) | Ester compound and preparation method and application thereof | |
| CN107922448B (en) | Deuterated thienopiperidine derivative, preparation method and application thereof | |
| CN102351878B (en) | Isoxazole derivatives as well as preparation method and application thereof | |
| CN102268012B (en) | Thiazole derivative and preparation method and application thereof | |
| CN105026399B (en) | As the pyrrolo-triazine class compound of potassium channel inhibitors | |
| CN102268013B (en) | Thiadiazole derivative as well as preparation method and application thereof | |
| CN101830911B (en) | Thienopyridine derivatives, preparation method and application thereof | |
| CN101619039B (en) | 2-(4-ethyl-1-piperazinyl)-4-(4-fluorophenyl)-5,6,7,8,9,10-hexahydro-cycloocta[b]pyridine (blonanserin, Blonanserin) and composition thereof | |
| WO2000016776A1 (en) | Sustained release oral preparations | |
| CN102796040A (en) | 1,4-disubstituted piperazine derivatives and their preparation method and use | |
| CN102796093B (en) | Thiomorpholine-containing pyrrole derivatives and their preparation method and use | |
| CN103304561B (en) | One class has the compound of anti thrombotic action | |
| CN101863900B (en) | Novel nitric oxide donating thienopyridine derivative and preparation method and application thereof | |
| CN101781310A (en) | Thiofuran-pyridine [3, 2-c] contained acethydrazide derivative and preparation method and application thereof | |
| CN102276626B (en) | Isoxazole-containing compound | |
| JP2000154137A (en) | Sustained release oral formulation | |
| KR20200129705A (en) | PI3K Inhibitor of Amorphous and Pharmaceutical Composition Comprising the same |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant |